Regenicin, Inc. (RGIN)

0.0050 0.0000 (0.00%) At close: 10:16AM EDT

Regenicin, Inc.

10 High Court
Little Falls, NJ 07424
United States
973 557 8914
https://www.regenicin.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 3

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Randall E. McCoy	Chairman, CEO & President	250k	N/A	1949
Mr. John J. Weber	CFO & Director	125k	N/A	1950
Dr. J. Roy Nelson Ph.D.	Controller & Chief Science Officer	150k	N/A	1948

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey.

Corporate governance

Regenicin, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.